68Ga-grazytracer PET/CT in Subjects With Non-small Cell Lung Cancer or Melanoma
Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to
investigate the clinical predictive value of 68Ga-grazytracer in subjects with non-small cell
lung cancer or melanoma receiving immune checkpoint inhibitors (e.g., Ipilimumab, Nivolumab).
A single dose of 2.96 MBq/kg body weight of 68Ga-grazytracer will be injected intravenously.
The visual and semiquantitative methods will be used to assess the PET/CT images.